CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea

Summary

This is a multicenter, randomized, double-blind, vehicle-controlled, parallel design study evaluating the efficacy and safety of CGB-400 Topical Gel for the treatment of inflammatory lesions of rosacea. The study consists of a 12-week double-blind treatment period with clinic visits at Baseline (Day 0), and Weeks 2, 4, 8, and 12. Approximately 80 subjects will be enrolled and randomized at a 1:1 ratio to treatment with either CGB-400 Topical Gel (40%) BID or Vehicle Gel BID.

Timeline

Start

2021-05-07

Primary completion

2021-12-22

Completion

2021-12-22

Drugs

Indications